BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Mevrometostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Mevrometostat\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06551324-7732@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Mevrometostat: Phase 3 readout est. (NCT06551324)
DESCRIPTION:Mevrometostat\, phase 3.\nStudy: A Study to Learn About the Inv
 estigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC
  Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer 
 (MEVPRO-1).\nEstimated primary completion: 28 February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/mevrometostat#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06551324
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06629779-7732@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Mevrometostat: Phase 3 readout est. (NCT06629779)
DESCRIPTION:Mevrometostat\, phase 3\, Metastatic Castration-Resistant Prost
 ate Cancer.\nStudy: A Study to Learn How PF-06821497 (Mevrometostat) Works
  in Men With Metastatic Castration-resistant Prostate Cancer.\nEstimated p
 rimary completion: 30 September 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/mevrometostat#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06629779
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03460977-7732@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:Mevrometostat: Phase 1 readout est. (NCT03460977)
DESCRIPTION:Mevrometostat\, phase 1\, Metastatic Castration-Resistant Prost
 ate Cancer.\nStudy: A Study of Mevrometostat for Treatment of Relapsed/Ref
 ractory SCLC\, Castration Resistant Prostate Cancer\, and Follicular Lymph
 oma\nEstimated primary completion: 20 April 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/mevrometostat#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03460977
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07028853-7732@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20280912
DTEND;VALUE=DATE:20280913
SUMMARY:Mevrometostat: Phase 3 readout est. (NCT07028853)
DESCRIPTION:Mevrometostat\, phase 3.\nStudy: This Study Will Explore Whethe
 r a Combination of the Investigational Drug Mevrometostat (PF-06821497) an
 d Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Particip
 ants With mCSPC Who Are ARPI naïve.\nEstimated primary completion: 12 Sep
 tember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mevromet
 ostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07028853
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07592910-7732@assetmemo.bio
DTSTAMP:20261121T004115Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Mevrometostat: Phase 2 readout est. (NCT07592910)
DESCRIPTION:Mevrometostat\, phase 2.\nStudy: A Study of Mevrometostat With 
 Enzalutamide in People With Prostate Cancer Who Have Previously Received A
 ndrogen Receptor Pathway Inhibitor Therapy\nEstimated primary completion: 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mevrometost
 at#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7592910
URL:https://assetmemo.bio/drug/mevrometostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
